Glaukos (GKOS): Company Profile & Investor Guide

Quick answer

Glaukos is an ophthalmic medical-technology and pharmaceutical company focused on glaucoma, corneal disorders and retinal disease. Its investment case has changed materially as the company has expanded from implantable glaucoma devices into drug-delivery and corneal therapies. In 2026, the two products investors most need to understand are iDose TR, an intracameral sustained-release glaucoma therapy, and Epioxa, a corneal cross-linking therapy. The central question is no longer whether Glaukos can invent useful eye-care technology; it is whether it can convert a broader product portfolio into durable adoption, reimbursement, operating leverage and eventually sustained profitability.

This page is an educational research guide, not a recommendation to buy or sell GKOS. The goal is to identify the business engine, the metrics that matter, what could improve the economics, what could break the thesis, and where investors can verify the facts themselves.

Company snapshot

| Field | Detail | |---|---| | Company | Glaukos Corporation | | Ticker | GKOS | | Exchange | NYSE | | Research framework | Medtech | | Canonical Swoopr route | `/stocks/companies/glaukos/` | | Index relationship | S&P SmallCap 600 candidate/current relationship must be verified against approved S&P data before public labeling | | Research date | September 6, 2026 |

The index relationship belongs on the company entity; it should not create a second company article under an index-specific URL. If Glaukos later changes capitalization segments, Swoopr should preserve the same canonical page and add an effective-dated membership event.

What Glaukos actually does

Glaukos sells therapies and devices used by ophthalmologists to treat diseases that can damage vision. Historically, the company became known for micro-invasive glaucoma surgery products. The economic model is now broader. Some products are implantable devices used during ophthalmic procedures, while newer therapies create recurring or repeatable treatment opportunities tied to drug delivery and corneal intervention. That portfolio transition matters because it can change both the addressable market and the mix of reimbursement, physician adoption and sales effort required to grow.

A useful investor test is to describe the business without using the stock ticker. Ask: who pays the company, what problem is solved, how frequently does the customer pay, what resources must be reinvested to keep the revenue stream alive, and what makes switching difficult? Those answers are more durable than a daily price move.

Current operating snapshot

Glaukos reported second-quarter 2026 net sales of $185.6 million, up 50% year over year. Glaucoma net sales were $155.2 million and U.S. glaucoma sales were $118.5 million, up 64%. Management reported a GAAP gross margin of roughly 82% and a non-GAAP gross margin of roughly 85%. The company still recorded a GAAP net loss of $18.4 million, which illustrates the key tension in the story: the commercial engine is scaling rapidly, but investors still need to watch how fast operating expenses convert that growth into durable earnings. Cash, cash equivalents, short-term investments and restricted cash were approximately $289.3 million at quarter end, and the company reported no debt. Management's 2026 net-sales guidance was $680 million to $700 million.

Current-period figures should always be treated as a dated snapshot rather than timeless facts. The next filing can change the trend. Swoopr should therefore timestamp dynamic financial modules and keep historical values rather than overwriting them.

The numbers that matter most

• U.S. glaucoma net sales and growth : track the trend, management explanation and source.
• iDose TR adoption and repeat utilization : track the trend, management explanation and source.
• Epioxa launch trajectory : track the trend, management explanation and source.
• gross margin : track the trend, management explanation and source.
• operating expense growth versus revenue growth : track the trend, management explanation and source.
• cash and investments : track the trend, management explanation and source.
• GAAP operating loss and path to profitability : track the trend, management explanation and source.
• reimbursement coverage and physician access : track the trend, management explanation and source.

Physician adoption, reimbursement breadth, repeat utilization and gross-to-net pricing matter more than a one-time shipment spike.

The purpose of this dashboard is not to maximize the number of statistics on the page. It is to select the small set of operating variables that explain most of the change in business value. Investors should be able to update the thesis after an earnings report by revisiting these metrics rather than rereading an entire narrative from scratch.

History and strategic evolution

Glaukos built its identity around micro-invasive glaucoma surgery, helping establish a treatment category between topical medications and more invasive surgery. Over time, management broadened the company from a device-centric story into a multi-modality ophthalmic platform. The launch of iDose TR was an especially important strategic pivot because it brought sustained-release pharmaceutical delivery into the glaucoma franchise. Epioxa expands the company further into corneal disease. For investors, the useful historical question is whether each new platform has expanded Glaukos's economics without diluting focus. A successful transition would make the business less dependent on any single surgical product and more relevant across the treatment pathway.

A company timeline should focus on events that changed economics: founding, IPO, major acquisitions, divestitures, product launches, regulatory approvals, restructuring, leadership transitions, debt recapitalizations and index migrations. A date is not useful merely because it happened; it belongs on the timeline when it changed what the company could earn, how much capital it required, or what could go wrong.

Competitive advantages

Glaukos's potential advantages come from ophthalmologist relationships, clinical evidence, procedure and reimbursement experience, and a portfolio that can address different points in the treatment continuum. Physician workflow matters: a therapy that is clinically useful but difficult to adopt or reimburse can struggle commercially. The company therefore benefits if its products become familiar tools inside established ophthalmic practices. The advantage is not invulnerable. Large eye-care companies have deeper commercial resources, and new drugs or devices can change treatment standards.

The strongest way to test a claimed moat is to ask what a capable, well-funded competitor would need to do to take customers away. If the answer is “offer a slightly lower price,” the moat is weak. If the answer requires years of qualification, network density, regulatory evidence, installed infrastructure, unique data or deeply embedded workflow, the advantage is more defensible. Swoopr should describe evidence for each advantage and also state what could weaken it.

Balance sheet and capital allocation

The absence of debt and a sizable cash/investment position provide strategic flexibility, but a net loss means liquidity still deserves attention. The right question is not simply “Does Glaukos have cash?” but whether future operating cash generation can reduce dependence on the balance sheet as commercialization scales. Share-based compensation and diluted share count should be tracked alongside headline revenue because per-share value is what ultimately matters.

Capital allocation is management's second product. After the operating business generates or consumes cash, leaders decide whether to reinvest, acquire, repay debt, repurchase shares, pay dividends or hold liquidity. Small-cap investors should judge those choices on per-share value creation. Revenue growth funded by excessive equity issuance or expensive debt can make the company larger while leaving shareholders worse off.

Dilution and per-share economics

Track basic and diluted shares outstanding across at least five years when history is available. Identify stock-based compensation, secondary offerings, converts, acquisition consideration and repurchases. A rising share count is not automatically bad:issuing stock can fund a value-creating acquisition or extend a critical development runway:but the burden of proof is economic. Ask whether intrinsic value per share grew faster than the share count.

For companies that repurchase shares, use the same standard. Buybacks are not inherently shareholder-friendly. Compare the repurchase price with normalized earning power and examine whether repurchases merely offset employee stock compensation.

Bull, base and bear framework

### Bull case The bull case is not “the stock goes up.” It requires an operating path in which Glaukos compounds its most important KPIs faster than the market expects, converts that improvement into stronger cash economics, and preserves enough competitive advantage to sustain the result. In that scenario, investors may receive both fundamental growth and a more favorable valuation if prior skepticism was excessive.

### Base case The base case assumes neither heroic execution nor collapse. Revenue and operating metrics progress in line with current evidence, margins normalize toward a defensible level, the balance sheet remains manageable, and management allocates capital without a major error. The base case should be updated after each filing, not treated as a permanent forecast.

### Bear case The biggest risks are commercialization execution, reimbursement, competition, clinical/regulatory setbacks in the pipeline, and the possibility that operating expenses remain structurally high even as sales grow. Product concentration still matters despite diversification. A fast launch can also create misleading expectations if early adopters are not representative of the broader physician base. Investors should distinguish shipment growth from sustained utilization and watch whether gross profit converts into improving operating economics.

The bear case should explicitly connect the failure mode to numbers. Which KPI deteriorates first? How much liquidity is available? Could management cut spending? Would debt or dilution become necessary? A useful bear case tells the investor what evidence would invalidate the thesis before the stock price does.

Risk matrix

| Risk | Why it matters | Early signal | |---|---|---| | Execution | Strategy can fail even when the market opportunity is real. | Missed milestones, weaker guidance or slipping KPIs | | Balance sheet | Small/mid-sized companies have less room for financing mistakes. | Rising leverage, falling liquidity or expensive issuance | | Competition | Better-funded competitors can compress growth or margins. | Pricing pressure, lost customers/designs or rising acquisition cost | | Valuation | Strong operations can still be a poor investment if expectations are extreme. | Multiple expansion without matching fundamental improvement |

What could go wrong that investors may underestimate?

Small-cap equities often fail through combinations rather than one dramatic event. Slower growth can coincide with higher financing costs. A product delay can reduce revenue while forcing R&D to remain elevated. A cyclical downturn can expose leverage that looked harmless at peak earnings. That is why downside analysis should combine operating and financing stress rather than moving one assumption at a time.

A practical exercise is to build a “bad year” model: reduce the company's primary volume/growth driver, compress margin, assume no favorable multiple expansion, and add realistic financing needs. If the company still has strategic flexibility, the balance sheet is an asset. If the scenario immediately requires dilutive equity or distressed refinancing, risk is higher than the headline growth rate suggests.

### How to think about valuation A development-and-commercialization medtech company should not be valued from one quarter's EPS. A more useful framework starts with addressable treated patients, adoption curves, net selling economics, gross margin and the operating expense required to support the commercial infrastructure. As products mature, investors can transition toward revenue multiples, operating-margin potential and free cash flow. The key is to avoid assigning mature-company margins before reimbursement and physician adoption are proven.

### Filing walkthrough Start with the 10-K business section to map approved products and pipeline programs. Then read revenue recognition and segment disclosures, followed by risk factors on reimbursement, regulatory approvals and intellectual property. In each 10-Q, reconcile product-sales commentary with receivables, inventory, operating expenses and cash. Finally, review the diluted share count and stock-compensation footnote so commercial progress is measured per share.

Early-warning signals

| Warning signal | Why it matters | Where to check | |---|---|---| | Core KPI decelerates for multiple periods | May indicate demand, execution or competitive deterioration | 10-Q, earnings release, KPI table | | Gross/operating margin weakens despite scale | Can signal poor mix, pricing pressure or cost creep | Income statement and segment notes | | Cash conversion trails adjusted earnings | Adjusted metrics may be overstating economic progress | Cash-flow statement | | Share count accelerates | Per-share value may lag business growth | EPS/share footnotes, proxy, 10-Q | | Net leverage rises | Reduces flexibility in a downturn | Balance sheet and debt footnotes | | Management changes definitions or stops reporting a KPI | Can make deterioration harder to see | Compare current and prior filings |

One quarter rarely proves a structural change. The goal is to identify patterns early and then investigate the cause.

What investors often misunderstand about Glaukos

1. Revenue growth is not the same as value creation. Growth must be evaluated against margin, capital intensity, dilution and balance-sheet risk.

2. Adjusted earnings are not cash. Reconcile management's preferred measures to GAAP and then to free cash flow.

3. Index membership does not validate the investment thesis. The S&P SmallCap 600 is a benchmark, not an endorsement.

4. A strong product does not guarantee a strong stock return. Expectations and valuation matter.

5. A low valuation multiple is not automatically cheap. Normalized earnings can fall, debt can claim more of enterprise value, or a supposedly temporary problem can become structural.

Quarterly investor checklist

• [ ] Quarterly u.s. glaucoma sales
• [ ] Idose tr reorder/adoption commentary
• [ ] Epioxa reimbursement and commercial milestones
• [ ] Gross margin
• [ ] R&d and sg&a growth
• [ ] Cash balance and cash use
• [ ] New clinical/regulatory milestones
• [ ] Diluted share count
• [ ] Read the latest 10-Q rather than relying only on the earnings presentation
• [ ] Compare diluted shares with the prior-year period
• [ ] Reconcile adjusted earnings to operating and free cash flow
• [ ] Update the bull/base/bear assumptions
• [ ] Record any new debt maturity, litigation, regulatory or customer-concentration disclosure

How to research Glaukos yourself

• 10-K: map the business, segments, risk factors, debt and five-year history.
• 10-Q: update the operating model and identify what changed since year-end.
• 8-K / earnings release: capture the newest KPIs and guidance, but reconcile non-GAAP metrics to filings.
• Proxy: study ownership, executive incentives, board structure and dilution.
• Investor presentations: useful for strategy and operating metrics, but management-selected; verify against filings.
• Competitor filings: test whether industry explanations are company-specific or sector-wide.

The highest-quality research process tries to disprove its own thesis. Search the filing for the words customer, concentration, debt, covenant, liquidity, competition, material weakness, litigation, stock compensation, impairment and restructuring. Those searches often surface information that slide decks minimize.

Decision framework: what would change the thesis?

Before owning any company, write down three pieces of evidence that would make you more optimistic and three that would make you less optimistic. For Glaukos, the monitoring list above is the starting point. Tie each item to a numeric threshold or direction when possible. For example, “growth slows” is vague; “the core operating KPI decelerates for three consecutive quarters while customer acquisition spending rises” is testable.

This discipline reduces hindsight bias. A stock-price decline alone does not prove the thesis is wrong, just as a rally does not prove it is right. The thesis changes when evidence about future cash generation, competitive position, financing needs or per-share economics changes.

FAQs

### What does Glaukos do?

Glaukos sells therapies and devices used by ophthalmologists to treat diseases that can damage vision. Historically, the company became known for micro-invasive glaucoma surgery products. The economic model is now broader. Some products are implantable devices used during ophthalmic procedures, while newer therapies create recurring or repeatable treatment opportunities tied to drug delivery and corneal intervention. That portfolio transition matters because it can change both the addressable market and the mix of reimbursement, physician adoption and sales effort required to grow.

### How does Glaukos make money?

Glaukos sells therapies and devices used by ophthalmologists to treat diseases that can damage vision. Historically, the company became known for micro-invasive glaucoma surgery products. The economic model is now broader. Some products are implantable devices used during ophthalmic procedures, while newer therapies create recurring or repeatable treatment opportunities tied to drug delivery and corneal intervention. That portfolio transition matters because it can change both the addressable market and the mix of reimbursement, physician adoption and sales effort required to grow.

### What are the most important numbers to watch?

The most useful dashboard is: U.S. glaucoma net sales and growth, iDose TR adoption and repeat utilization, Epioxa launch trajectory, gross margin, operating expense growth versus revenue growth. These metrics connect the company narrative to measurable operating evidence.

### What is the biggest risk?

The biggest risks are commercialization execution, reimbursement, competition, clinical/regulatory setbacks in the pipeline, and the possibility that operating expenses remain structurally high even as sales grow. Product concentration still matters despite diversification. A fast launch can also create misleading expectations if early adopters are not representative of the broader physician base. Investors should distinguish shipment growth from sustained utilization and watch whether gross profit converts into improving operating economics.

### What could make the company perform better than expected?

The upside case depends on Glaukos converting its strategic position into faster durable growth, better margins and stronger per-share cash generation without taking disproportionate balance-sheet risk.

### What could go wrong?

The downside case is not simply a lower stock price. It is a business outcome in which Glaukos misses the operating milestones described in this guide while capital intensity, competition or financing absorbs more value than expected.

### How should investors use the balance sheet?

The absence of debt and a sizable cash/investment position provide strategic flexibility, but a net loss means liquidity still deserves attention. The right question is not simply “Does Glaukos have cash?” but whether future operating cash generation can reduce dependence on the balance sheet as commercialization scales. Share-based compensation and diluted share count should be tracked alongside headline revenue because per-share value is what ultimately matters.

### Why is GKOS considered a small-cap research opportunity?

Index placement tells investors that GKOS currently sits in the small-cap segment under S&P's benchmark framework; it does not determine quality. The research opportunity comes from doing primary-source work on a company that may receive less broad-market attention than mega-caps.

### What should investors read first?

Begin with the latest 10-K, then the latest 10-Q and earnings release. Use https://investors.glaukos.com/financials/annual-reports/default.aspx as a primary starting point, and compare management commentary with the actual financial statements and share-count data.

### Is index membership an investment recommendation?

No. S&P SmallCap 600 membership is a benchmark-classification decision, not a buy or sell recommendation. Investors still need an independent thesis, valuation and risk assessment.

Internal-link opportunities for Swoopr

Link this company page to:

• S&P SmallCap 600 index guide
• relevant sector and industry hub
• market-capitalization glossary
• free-cash-flow guide
• dilution and stock-compensation explainers
• debt and leverage guides
• valuation-method pages appropriate to the business model
• direct competitors with canonical Swoopr company pages
• relevant ETF/index pages
• risk-management and portfolio-construction guides

Links should be contextual. Do not add hundreds of boilerplate links simply because a relationship exists in the knowledge graph.